Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma.

Andreadis C, Gimotty PA, Wahl P, Hammond R, Houldsworth J, Schuster SJ, Rebbeck TR.

Blood. 2007 Apr 15;109(8):3409-16. Epub 2006 Dec 19.

2.

Prognostic biomarkers in diffuse large B-cell lymphoma.

Lossos IS, Morgensztern D.

J Clin Oncol. 2006 Feb 20;24(6):995-1007. Epub 2006 Jan 17. Review.

PMID:
16418498
3.

A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis.

Tome ME, Johnson DB, Rimsza LM, Roberts RA, Grogan TM, Miller TP, Oberley LW, Briehl MM.

Blood. 2005 Nov 15;106(10):3594-601. Epub 2005 Aug 4.

4.

Algorithmic fusion of gene expression profiling for diffuse large B-cell lymphoma outcome prediction.

Zhu Q, Cui H, Cao K, Chan WC.

IEEE Trans Inf Technol Biomed. 2004 Jun;8(2):79-88.

PMID:
15217252
5.

Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma.

Linderoth J, Edén P, Ehinger M, Valcich J, Jerkeman M, Bendahl PO, Berglund M, Enblad G, Erlanson M, Roos G, Cavallin-Ståhl E.

Br J Haematol. 2008 May;141(4):423-32. doi: 10.1111/j.1365-2141.2008.07037.x.

PMID:
18419622
6.

Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas.

van Galen JC, Muris JJ, Giroth CP, Vos W, Ossenkoppele GJ, Meijer CJ, Oudejans JJ.

Histopathology. 2008 Apr;52(5):578-84. doi: 10.1111/j.1365-2559.2008.02970.x. Epub 2008 Feb 23.

PMID:
18312353
7.

Prognostic significance of BACH2 expression in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group.

Sakane-Ishikawa E, Nakatsuka S, Tomita Y, Fujita S, Nakamichi I, Takakuwa T, Sugiyama H, Fukuhara S, Hino M, Kanamaru A, Soma T, Tsukaguchi M, Igarashi K, Kanakura Y, Aozasa K; Osaka Lymphoma Study Group.

J Clin Oncol. 2005 Nov 1;23(31):8012-7.

PMID:
16258099
8.

Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.

Oki Y, Yamamoto K, Kato H, Kuwatsuka Y, Taji H, Kagami Y, Morishima Y.

Eur J Haematol. 2008 Dec;81(6):448-53. doi: 10.1111/j.1600-0609.2008.01129.x. Epub 2008 Aug 6.

PMID:
18691256
9.

Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response.

Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, Wu B, Pasqualucci L, Neuberg D, Aguiar RC, Dal Cin P, Ladd C, Pinkus GS, Salles G, Harris NL, Dalla-Favera R, Habermann TM, Aster JC, Golub TR, Shipp MA.

Blood. 2005 Mar 1;105(5):1851-61. Epub 2004 Nov 18.

10.

Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas.

Ferreri AJ, Dell'Oro S, Capello D, Ponzoni M, Iuzzolino P, Rossi D, Pasini F, Ambrosetti A, Orvieto E, Ferrarese F, Arrigoni G, Foppoli M, Reni M, Gaidano G.

Br J Haematol. 2004 Sep;126(5):657-64.

PMID:
15327516
11.

Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling.

Sakhinia E, Glennie C, Hoyland JA, Menasce LP, Brady G, Miller C, Radford JA, Byers RJ.

Blood. 2007 May 1;109(9):3922-8. Epub 2007 Jan 25.

12.

Evaluation of MIB-1 and p53 overexpression as risk factors in large cell non-Hodgkin lymphoma in adults.

El-Bolkainy TN, El-Bolkainy MN, Khaled HM, Mokhtar NM, Eissa SS, Gouda HM, El-Hattab OH.

J Egypt Natl Canc Inst. 2007 Dec;19(4):231-8.

13.

Diagnostic and prognostic significance of gene expression profiling in lymphomas.

Leich E, Hartmann EM, Burek C, Ott G, Rosenwald A.

APMIS. 2007 Oct;115(10):1135-46. Review.

PMID:
18042147
14.

Emerging prognostic factors in diffuse large B cell lymphoma.

Gascoyne RD.

Curr Opin Oncol. 2004 Sep;16(5):436-41. Review.

PMID:
15314511
15.

HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma.

Lossos IS, Alizadeh AA, Rajapaksa R, Tibshirani R, Levy R.

Blood. 2003 Jan 15;101(2):433-40.

16.

MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosis.

Hsi ED, Sup SJ, Alemany C, Tso E, Skacel M, Elson P, Alonso MA, Pohlman B.

Am J Clin Pathol. 2006 May;125(5):776-82.

PMID:
16707382
17.

Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP.

Malumbres R, Chen J, Tibshirani R, Johnson NA, Sehn LH, Natkunam Y, Briones J, Advani R, Connors JM, Byrne GE, Levy R, Gascoyne RD, Lossos IS.

Blood. 2008 Jun 15;111(12):5509-14. doi: 10.1182/blood-2008-02-136374. Epub 2008 Apr 29.

18.
19.

PKC-beta II expression has prognostic impact in nodal diffuse large B-cell lymphoma.

Schaffel R, Morais JC, Biasoli I, Lima J, Scheliga A, Romano S, Milito C, Spector N.

Mod Pathol. 2007 Mar;20(3):326-30. Epub 2007 Jan 19.

20.

Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma.

Rodig SJ, Savage KJ, LaCasce AS, Weng AP, Harris NL, Shipp MA, Hsi ED, Gascoyne RD, Kutok JL.

Am J Surg Pathol. 2007 Jan;31(1):106-12.

PMID:
17197926

Supplemental Content

Support Center